Dihexa and cognition: what the rat studies actually show

What did @dr..alex.tatem actually say?

The creator described Dihexa as a small, orally active peptide developed at Washington State University that works by activating hepatocyte growth factor (HGF) signaling in the brain. They credited it with promoting neurogenesis and neuroplasticity in animal models, suggested potential relevance to neurodegenerative conditions, and then pulled the brakes: "human clinical data on Dihexa, virtually non-existent." They also flagged gray-market sourcing as a real risk and landed on "limitless in theory, questionable in practice."

That's a reasonably honest summary for a 60-second TikTok. The creator doesn't promise cognitive transformation or tell viewers to buy anything. The skepticism is genuine, not performative. That matters more than it might seem on a platform where peptide hype runs rampant.

Does the science back this up?

Yes, mostly. The foundational animal research is real, and the HGF mechanism is legitimate neuroscience. But the creator leans on rodent data harder than the evidence probably warrants without flagging just how far that data is from clinical application.

Dihexa (also called PNB-0408) was developed by Joseph Harding and colleagues at Washington State University. A widely cited 2013 study published in the Journal of Pharmacology and Experimental Therapeutics (McCoy et al., 2013) showed that Dihexa outperformed the cognitive effects of BDNF in a scopolamine-induced amnesia rat model by several orders of magnitude in potency. That's the rodent data everyone cites. It's real. It's also from 2013, and there has been no published randomized controlled trial in humans since. The mechanism, enhancing HGF/c-Met signaling to promote synaptogenesis, is biologically plausible. HGF is expressed in the brain and does support neuronal survival and synaptic remodeling (Korhonen et al., 2000, Experimental Neurology). The leap from plausible mechanism plus rodent results to human cognitive enhancement, however, is a leap the evidence has not made.

What did they get wrong (or right)?

They got the core facts right. They got a few details sloppy. And they missed one risk worth naming explicitly.

On the factual side: the WSU origin, the HGF mechanism, the rodent-only evidence base, the lack of FDA approval, and the gray-market sourcing problem are all accurately described. Credit where it's due.

The sloppiness: at one point the creator says "HHF signaling" instead of HGF. Minor verbal slip, but in a health video watched by 200K people, precision matters. More substantively, the creator briefly mentions Alzheimer's, Parkinson's, and dementia as potential targets. That framing edges toward implying Dihexa could treat these diseases. It cannot, based on current evidence, and calling it a potential therapeutic "in the future" without a harder disclaimer risks giving viewers false hope about a completely unproven compound.

The missed risk: HGF signaling is not consequence-free. HGF and its receptor c-Met are implicated in tumor growth and metastasis in several cancer types (Christensen et al., 2005, Cancer Research). Chronically upregulating this pathway in healthy humans is not a proven-safe move. The creator should have said that plainly.

What should you actually know?

Dihexa is genuinely interesting as a research compound. It is not a supplement, not a therapy, and not something with a known human safety profile.

• No published human clinical trials exist for Dihexa as of 2024. The pipeline from rodent cognition studies to approved human treatments takes an average of 12-plus years and fails more than 90 percent of the time (Hay et al., 2014, Nature Biotechnology).
• Sourcing Dihexa through gray-market vendors means you have no verified information on purity, concentration, or contamination. Third-party certificate of analysis documents from these vendors are frequently unreliable.
• The HGF/c-Met pathway that Dihexa targets is the same pathway studied in oncology for its role in cancer progression. This is not a reason to panic, but it is a reason why "wait for clinical trials" is not just regulatory caution. It is basic prudence.
• Placebo effects in unblinded self-experimentation with nootropics are well-documented and substantial (Colagiuri et al., 2012, Experimental and Clinical Psychopharmacology). The biohacker testimonials the creator references are not evidence.